WILMINGTON, DE — NRx Pharmaceuticals (Nasdaq: NRXP) said it supports an executive order signed April 18, 2026, directing federal agencies to accelerate research and regulatory pathways for treatments targeting serious mental illness, including psychedelic-based therapies.
The order calls for expanded clinical research, increased data sharing, and expedited approval processes for drugs addressing conditions such as depression, post-traumatic stress disorder, and suicidality.
It also directs the Food and Drug Administration to issue National Priority Vouchers for qualifying therapies with Breakthrough Therapy designation and to coordinate with the Department of Health and Human Services and the Department of Veterans Affairs to expand clinical trial participation…